HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NCCAM Slowing Research Pace, Turning To Program Announcements

This article was originally published in The Tan Sheet

Executive Summary

The National Center for Complementary & Alternative Medicine will issue proportionately more program announcements (PAs) in the coming year than requests for applications (RFAs), hedging against a possible upsurge of out-year costs for funded grants.

You may also be interested in...

CAM Cancer Research Targeted In NCCAM-NCI Program Announcement

NCCAM and the National Cancer Institute issued a program announcement Dec. 17 seeking to stimulate research into complementary and alternative cancer therapies

NCCAM Funding For Botanical/HIV Drug Interaction Research Set At $600,000

Grant requests for Phase I/II clinical studies on botanicals' interaction with HIV drugs should "examine the pharmacokinetics or pharmacodynamics of the botanical/drug combination" compared to lone use of either product, the National Center for Complementary & Alternative Medicine says

Cranberries & UTIs

NCCAM calls for supplies of cranberry juice cocktail, concentrate and encapsulated powders, with matching placebos, in Request For Information posted on center's Web site. Collected cranberry products will be used in "NIH-supported research, specifically (but not exclusively) for basic and clinical research on the role of cranberry (Vaccinium macrocarpon) in the prevention and treatment of urinary tract infections." Request marks an initial step in cranberry initiative approved at NCCAM's advisory council meeting Aug. 27 (1"The Tan Sheet" Sept. 3, p. 4)

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts